Lupin supplies the second largest amount of generic drugs to the U.S. From October to December of last year, the U.S. market made up 49.4 percent of Lupin’s sales.
While President Donald Trump’s proposed border adjustment tax aims to encourage more manufacturing in the U.S. by implementing a tariff on imported goods, Mr. Gupta said the tax could adversely affect supply chains and cause higher costs for Indian drugmakers importing generic drugs into the U.S.
The drugmaker plans to launch 25 new products in the U.S. in fiscal year 2018.
More articles on supply chain:
Why pharmacists can’t speak up when they know customers are overpaying for drugs
LCMC Health partners with The Resource Group for supply chain services
Pharma leaders, healthcare experts advocate value-based payments for drugs
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
